(Q33989047)

30 July 2017

Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study (English)

1 reference

30 July 2017

0 references

anti-retroviral agent

0 references

9

Matthias Egger

0 references

Kate Tilling

object named as

Kate Tilling

4

0 references

Swiss HIV Cohort Study

10

object named as

Swiss HIV Cohort Study

1 reference

30 July 2017

3

Bruno Ledergerber

1 reference

ORCID Public Data File 2021

30 July 2017

1 reference

Jonathan Sterne

1

object named as

Jonathan A C Sterne

1 reference

30 July 2017

Miguel A Hernán

2

1 reference

30 July 2017

Rainer Weber

5

1 reference

30 July 2017

Pedram Sendi

6

1 reference

30 July 2017

Martin Rickenbach

7

1 reference

30 July 2017

James M Robins

8

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

30 July 2017

1 reference

30 July 2017

366

1 reference

30 July 2017

9483

1 reference

30 July 2017

378-384

1 reference

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

A structural approach to selection bias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Marginal structural models and causal inference in epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Fetal origins of adult disease-the hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

HIV prevention before HAART in sub-Saharan Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Effect of Highly Active Antiretroviral Therapy on Time to Acquired Immunodeficiency Syndrome or Death using Marginal Structural Models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

HIV drug resistance--a chink in the armor.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Epidemiology, evolution, and future of the HIV/AIDS pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2805%2967022-5

7 January 2021

10.1016/S0140-6736(05)67022-5

Identifiers

DOI

1 reference

release_wy6er2loxvazflzgp6ghb7ryam

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wy6er2loxvazflzgp6ghb7ryam

24 November 2022

mapped directly with Wikidata item

1 reference